Neumora Therapeutics’ Collaboration With Amgen

Latham & Watkins represented Neumora in the deal.

Amgen and Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration to advance neuroscience discovery, development and commercialization. The companies will collaborate on programs by applying Neumora’s proprietary precision neuroscience platform to insights generated by Amgen’s deCODE genetics and human data research capabilities. In addition, Neumora has received a US$100 million equity investment from Amgen and acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. 

Latham & Watkins represented Neumora in the strategic collaboration agreement and equity investment with a Bay Area corporate team. Bay Area partner Brian Cuneo (Picture) led the team on investment and corporate matters, and Bay Area Partner Judith Hasko led the team on collaboration matters, with Bay Area associate Peggy Ni. Advice was also provide on tax matters by Bay Area partner Kirt Switzer with Bay Area associate Jessica Chen and on antitrust matters by Washington, D.C. counsel Peter Todaro.

Involved fees earner: Jessica Chen – Latham & Watkins; Brian Cuneo – Latham & Watkins; Judith Hasko – Latham & Watkins; Peggy Ni – Latham & Watkins; Kirt Switzer – Latham & Watkins; Peter Todaro – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Neumora Therapeutics;